IP Library Granted Patent US 7,304,029
Granted Patent B1
US 7,304,029 · App. 09/786,982 · Granted Dec 4, 2007

Neuroprotective effect of growth hormone

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,304,029
App. No.
09/786,982
Granted
Dec 4, 2007
Kind
B1
Abstract

The invention relates to neuroprotection and to medicaments for use therein. Neuroprotection is induced by activation of neural growth hormone receptors, primarily using medicaments comprising growth hormone, growth hormone analogs or ligands which are functionally equivalent. Such medicaments may also include one or more secondary neuroprotective agents.

Claims (7)

1. A method for inducing a neuroprotective effect of rescuing neurons destined to degenerate or die as a result of hypoxia or ischemia in a brain of a patient, comprising administering growth hormone centrally to the brain of the patient.

2. The method of claim 1 , where the neural rescue effect is the rescue of neurons otherwise destined to die as the result of a prior hypoxia or ischema.

3. The method of claim 1 further comprising administering to said patient, a pharmaceutically effective amount of a substance selected from the group consisting of growth hormone releasing peptides (GHRP), GHRP-1, GHRP-2, GHRP-6, Hexarel in, G-7039, G-7502, L-692,429, L-692,585, L-163,191, growth hormone releasing hormone (GHRH), prolactin, placental lactogen and somatostatin (somatotropin release inhibitory factor; SRIF).

4. The method of claim 1 further comprising administering a secondary neuroprotective agent.

5. The method of claim 4 where the secondary neuroprotective agent is selected from the group consisting of IGF-1, GPE, activin, NGF, TGF-β, growth hormone binding proteins, IGF-binding proteins and bFGF.

6. The method of claim 1 wherein said patient suffers from stroke.

7. The method of claim 1 , wherein the route of administration of said growth hormone is via lumbar, intracerebroventricular (ICV), intraventricular, intraparenchymal, or olfactory neural route.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2005
From: SCHEEPENS, ARJAN; WILLIAMS, CHRIS E.; GLUCKMAN, PETER DAVID; CLARK, ROSS GRAHAM
To: NEURONZ LIMITED
Reel/Frame 015690/0215 →
MERGER/CHANGE OF NAME Recorded Jan 31, 2005
From: NEURONZ LIMITED
To: ENDOCRINZ LIMITED
Reel/Frame 015629/0561 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2004
From: NEURONZ LTD.
To: NEUREN PHARMACEUTICALS LTD.
Reel/Frame 015511/0358 →